Division of General Surgery
GRANT RESEARCH
Falk Medical Trust
7/1/2002- 6/30/2005
P.I.: Robert Ausman, MD
STUDY AND ENHANCEMENT OF TREATMENT FOR HEPATIC METASTASIS FROM COLON CANCER
Three modes of therapy are available for treating cancer in the liver: surgery, chemotherapy, and ablation. This research is designed to enhance the understanding and clinical success of each.
NIH-NHLBI
12/1/2001- 11/30/2005
P.I. John E. Baker, PhD
C.I. Parvaneh Rafiee, PhD
CHRONIC HYPOXIA AND RESISTANCE TO MYOCARDIAL ISCHEMIA
This grant determines whether protein kinases contribute to cardioprotection in chronically hypoxic rabbit and human hearts.
NIH-NHLBI
9/30/2000- 8/31/2004
P.I. John E. Baker, PhD
C.I. Parvaneh Rafiee, PhD
GENETICS AND INTERMITTENT MYOCARDIAL HYPOXIA
Investigates the gene(s) responsible for adaptation to intermittent hypoxia that causes susceptibility to myocardial ischemia.
American Cancer Society
1/1/2003- 12/31/2004
P.I.: Bruce Brenner, MD
Co-Investigators: David M. Ota, MD, Mary F. Otterson, MD, Edward J. Quebbeman, MD, PhD, Philip N. Redlich, MD, PhD, Gordon L.Telford, MD, Alonzo P. Walker, MD, Richard A. Komorowski, MD, Barbara Susnik, MD, PhD, Kulwinder S. Dua, MD, Robert S. Hellman, MD, Raymond G. Hoffmann, PhD
GENOMIC INSTABILITY IN PREMALIGNANT COLORECTAL POLYPS
This study will evaluate the success rate of colorectal lymphatic mapping and sentinel lymph node biopsy. entinel lymph node biopsy will be performed in patients undergoing potentially curative resection for early‑stage colorectal cancer. Micrometastatic disease will be assessed in both bone marrow and lymph nodes in patients whose nodes are negative routine tests.
MCW Cancer Center
1/1/2003- 12/31/2004
P.I.: Bruce Brenner, MD
Co-Investigators: David M. Ota, MD, Mary F. Otterson, MD, Edward J. Quebbeman, MD, PhD, Philip N. Redlich, MD, PhD, Gordon L.Telford, MD, Alonzo P. Walker, MD, Richard A. Komorowski, MD, Barbara Susnik, MD, PhD, Kulwinder S. Dua, MD, Robert S. Hellman, MD, Raymond G. Hoffmann, PhD
GENOMIC INSTABILITY IN PREMALIGNANT COLORECTAL POLYPS
This study will evaluate the success rate of colorectal lymphatic mapping and sentinel lymph node biopsy. Sentinel lymph node biopsy will be performed in patients undergoing potentially curative resection for early‑stage colorectal cancer. Micrometastatic disease will be assessed in both bone marrow and lymph nodes in patients whose nodes are negative routine tests.
ACOSOG
10/1999 -
P.I.: Bruce M. Brenner, MD
Co-Investigators: David M. Ota, MD, Alonzo P. Walker, MD, Philip N. Redlich, MD, PhD, Gordon L. Telford, MD
ACOSOG Z0190: GENETIC STUDY OF THE PROGNOSTIC SIGNIFICANCE OF MICROSATELLITE INSTABILITY IN PATIENTS WITH EARLY AGE-OF-ONSET STAGE I-III COLORECTAL CANCER
This study will evaluate the prognostic significance (i.e. overall survival) of Microsatellite Instability (MSI) status assuming the presence of a quantitative interaction between MSI status and family history of cancer in patients with early age-of-onset (>18 years and <50 years) colorectal cancer. If the interaction term turns out to be insignificant, the prognostic significance of MSI status will be tested while adjusting for family history.
NIH-NHLBI
8/1/2003- 7/31/2006
P.I. Kirkwood Pritchard, PhD
C.I. Parvaneh Rafiee, PhD
C.I. Yang Shi, PhD
HSP90 MEDIATES ENOS AND VASCULAR FUNCTION
This grant is to elucidate the mechanisms by which heat shock protein 90 (Hsp90) modulates endothelial nitric oxide synthase function.
Cancer Center of MCW
1/1/2004- 12/31/2004
P.I. Parvaneh Rafiee, PhD
C.I. David G. Binion, MD
COX-2, IONIZING RADIATION AND COLONIC MICROVASCULAR ANGIOGENESIS IN COLORECTAL ADENOCARCINOMA
To characterize the role of cyclo-oxygenase 2 (COX-2) in human colonic microvascular endothelial cell angiogenesis mediated by VEGF.
Digestive Disease Center, MCW
8/1/2004-7/31/2005
P.I. Parvaneh Rafiee, PhD
C.I. David G. Binion, MD
SIGNALING ALTERATIONS ASSOCIATED WITH LOSS OF NO IN IBD ENDOTHELIAL CELLS
The goal of this project is to characterize alterations in signaling mechanisms in mucosal microvascular endothelial cells acquired during the course of chronic inflammation in patients with Crohn's disease using proteomic array analysis.
Learning Resources Grant
12/01/1999-6/30/2004
P.I.: Philip Redlich, MD
Co-Investigators: MCW Third-Year Clerkship Directors
UNDERSTANDING PROFESSIONAL AND UNPROFESSIONAL BEHAVIOR
Unprofessional behavior has been cited as commonly occurring in the clinical and pre-clinical environments within the medical school. The clerkship directors have created a videotape demonstrating various scenarios where professional and unprofessional behavior is exhibited. The viewing of this tape and discussion by students, residents and faculty serves to enhance the awareness of professionalism and ways to promote professional behavior.
Pharmacia & Upjohn Corporation
9/1/2002- 8/31/2005
P.I. Renae Stafford, MD
Co-Investigators: John Weigelt, MD, Mark Falimirsk, MD, Karen Brasel, MD, Ram Nirula, MD, Kathleen Christians, MD, and Louis Somberg, MD
A RANDOMIZED, OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL, COMPARING MICROBIOLOGICAL RESPONSE TO LINEZOLID AND VANCOMYCIN IN VENTILATOR-ASSOCIATED PNEUMONIA (VAP) DUE TO METHICILLIN RESISTANT STAPHLOCOCOUS AVREUS (MRSA)
This study looks at patients with ventilator-associated pneumonia due to methicillan resistant staphylococcus aureus. The enrolled patients, who have been hospitalized for relatively long stays and are on ventilators, are treated with either Linezolid or Vancomycin.
Dept of Defense
8/20/2001- 8/20/2004
P.I. Sonia Sugg, MD
USE OF A TRANSGENIC MOUSE MODEL WITH A REGULATABLE ESTROGEN RECEPTOR ALPHA (ER) TO STUDY THE ROLE OF ER IN MAMMARY GLAND DEVELOPMENT AND CANCER
To investigate how the timing of the estrogen receptor (ER) activation modulates normal mammary maturation and the development of mammary cancers.
Lady Riders Breast Cancer Research Foundation
9/14/2001- 6/30/2008
P.I. Sonia Sugg, MD
GENETIC DETERMINANTS OF RESISTANCE TO RAT MAMMARY CHEMICAL CARCINOGENESIS
Except for a small fraction of breast cancers due to hereditary syndromes, the genetic determinants of susceptibility to breast cancer in humans are largely unknown. Rat mammary cancers closely resemble human breast cancer. In various rat strains, there are differences in susceptibility to mammary cancer induced by chemicals. We are studying the genetic differences in rats that could cause resistance to mammary cancer. This is likely to involve many genes and signalling pathways. Results may be used to identify similar pathways and genes in human breast cancer.
MCW Cancer Center
1/1/2003- 12/31/2004
P.I. Sonia Sugg, MD
Co-Investigator: Stuart Wilson, MD
DIAGNOSIS OF THYROID NODULES BY GENE EXPRESSION PROFILE MICROARRAY ANALYSIS
To design a diagnostic test using genetic information to separate benign (noncancerous) thyroid nodules from malignant (cancerous) ones. There will be 100 subjects enrolled over a period of 5 years at MCW.
Med U of South Carolina Research Foundation
1/10/2001- 12/31/2006
P.I. Sonia Sugg, MD
Co-Investigators: Alonzo Walker, MD, Philip Redlich, MD, and Karen Brasel, MD
MI MOLECULAR STAGING (MIMS)
The purpose of this study is to compare the RT-PCR test with the standard tests to see which one better predicts whether your cancer comes back. The experimental aspect of this study is the use of the RT-PCR test to look for cancer cells in your lymph nodes, bone marrow, and blood. Neither you nor your doctor will be given the results of the RT-PCR test, because the significance of this test is not yet known.
ACOSOG
10/1999 -
P.I.: David M. Ota, MD
Co-Investigators: Alonzo P. Walker, MD, Philip N. Redlich, MD, PhD, Bruce M. Brenner, MD, Edward J. Quebbeman, MD, PhD, Paul S. Ritch, MD
ACOSOG Z9001: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF ADJUVANT STI571 (GLEEVEC™) VERSUS PLACEBO IN PATIENTS FOLLOWING THE RESECTION OF PRIMARY GASTROINTESTINAL STROMAL TUMOR (GIST)
A randomized, double-blind Phase III study of adjuvant STI571 (Gleevec™) versus placebo in patients with resected primary GIST that will determine whether patients who are randomized to the STI571 Arm have longer recurrence-free survival as compared to the patients randomized to the Placebo Arm. The study will also assess the safety and efficacy of oral STI571 therapy in the adjuvant setting.
NSABP Foundation Inc.
2/1/2001- 6/30/2008
P.I.: Alonzo Walker, MD
Co-Investigators: Philip N. Redlich, MD, PhD, Janet R. Hosenpud, MD, Julia R. White, MD
NSABP B-31: "A RANDOMIZED TRIAL COMPARING THE SAFETY AND EFFICACY OF ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOL (AC-T) TO THAT OF ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOL PLUS HERCEPTIN (AC-T + H) IN NODE-POSITIVE BREAST CANCER PATIENTS WHO HAVE TUMORS THAT OVEREXPRESS HER2"
Herceptin® (trastuzumab) has been shown to slow down the growth rate of cancers that over express Her2. This study will evaluate the efficacy and toxicity of Herceptin when added to standard chemotherapy in patients with early-stage breast cancer.
NSABP Foundation Inc.
2/1/2001- 6/30/2008
P.I.: Alonzo Walker, MD
Co-Investigators: David M. Ota, MD, Philip N. Redlich, MD, PhD, Sonia L. Sugg, MD, Janet R. Hosenpud, MD, Julia R. White, MD, Barbara Susnik, MD, PhD
NSABP B-35: "A CLINICAL TRIAL COMPARING ANASTROZOLE WITH TAMOXIFEN IN POSTMENOPAUSAL PATIENTS WITH DUCTAL CARCINOMA IN SITU (DCIS) UNDERGOING LUMPECTOMY WITH RADIATION THERAPY"
This Phase III randomized, double-blind study will evaluate the effectiveness of anastrozole compared to tamoxifen in preventing the subsequent occurrence of breast cancer in postmenopausal women with primary ductal carcinoma in situ (DCIS) that is ER/PgR positive and treated with lumpectomy and breast radiation.
ACOSOG
10/1999 -
P.I.: Alonzo Walker, MD
Co-Investigators: Philip N. Redlich, MD, PhD, Sonia L. Sugg, MD, David M. Ota, MD
ACOSOG Z0011: PHASE III RANDOMIZED STUDY OF AXILLARY LYMPH NODE DISSECTION IN WOMEN WITH STAGE I OR IIA BREAST CANCER WHO HAVE A POSITIVE SENTINEL NODE
A prospective randomized trial of axillary lymph node dissection versus no axillary dissection for patients who have a positive sentinel lymph node. Eligible patients can only have three or fewer positive lymph nodes with no extracapsular invasion.
Ductal Lavage Study
02/01/2002 – 6/30/2004
P.I.: Philip Redlich, M.D
Co-Investigators: Alonzo P. Walker, MD, Sonia L. Sugg, MD, Vinod Shidham, MD, Anna C. Purdy, RN, NP
A FEASIBILITY STUDY OF DUCTAL LAVAGE IN PATIENTS
Ductal lavage in selected high-risk women is a minimally invasive technique with minimal risk that allows cytologic sampling from an entire ductal tree from a discharging duct. Such information may allow further risk stratification with the potential for early detection of intraductal neoplastic disease not detectable by clinical exam or currently available breast imaging modalities. With additional risk-stratifying information, risk-reducing intervention such as chemoprevention with tamoxifen may be more accepted by the patient. Furthermore, once experience with ductal lavage is gained, the fluid could be analyzed with PCR or specific biomarkers that may detect neoplastic changes at a very early stage. This study will evaluate the feasibility and safety of the ductal lavage performed primarily by a nurse practitioner in selected high-risk women.
Return to top